BioSpace News Archive

Bionomics Limited announced it will present data on BNC210 for the treatment of Social Anxiety Disorder at the 2023 American Society of Clinical Psychopharmacology Annual Meeting taking place Tuesday, May 30, 2023, through Friday, June 2, 2023, in Miami Beach, Florida.

Regenative Labs the Pain and Sleep Therapy Center, has sponsored its own independent study approved by the Institutional Review Board (IRB) of the Institute of Cellular and Regenerative Medicine.

Tessa Therapeutics Ltd. announced two presentations featuring clinical data from the company’s autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy will be featured at the 17th International Conference on Malignant Lymphoma taking place from June 13-17, 2023, at Lugano, Switzerland.

MindBio Therapeutics Corp. demonstrates how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with Depression.

Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

SpringWorks Therapeutics, Inc. announced that it has achieved full enrollment in its Phase 2 trial evaluating nirogacestat, an investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, at 2:40 p.m. PT.

ProLung, Inc. dba IONIQ Sciences, Inc. announced that Mr. Jared Bauer, CEO, will present in-person at the 13th annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on June 6-8, 2023.

Castellum, Inc.today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market closes on June 23, 2023, according to a preliminary list of additions posted May 26, 2023.

Protalix BioTherapeutics, Inc. today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.